Global Vaccines Market Size By Age Group (Pediatric, Adult), By Technology (Attenuated, Toxoid, Conjugate, Inactivated & Subunit, Recombinant,), By Disease (Cancer, Hepatitis, Pneumococcal Disease, DTP, Dengue, Influenza, Human Papilloma Virus, Meningococcal Disease, Polio, Rotavirus), Regional Outlook (U.S., Canada, Germany, UK, Spain, Russia, Italy, France, China, Japan, India, Indonesia, Australia, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, UAE, Qatar, Egypt), Technology Development, Competitive Landscape & Forecast, 2017 – 2024

Published Date: November 2017 | 140 Pages | Report ID: GMI2186 Report Format: PDF

Inquiry Before Buying   Request Sample

Report Content

Chapter 1. Methodology

1.1. Methodology                      

1.1.1. Initial data exploration

1.1.2. Statistical modeling and forecast

1.1.3. Industry insights and validation

1.1.4. Market definition and forecast assumptions    

1.2. Data sources

1.2.1. Primary

1.2.2. Secondary

Chapter 2. Executive Summary

2.1. Global Vaccines industry 3600 synopsis, 2013 - 2024

2.1.1. Business trends

2.1.2. Age group trends

2.1.3. Disease trends

2.1.4. Technology trends

2.1.5. Regional trends

Chapter 3. Vaccines Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2013 – 2024

3.3. Industry impact forces

3.3.1. Growth drivers

3.3.1.1.    Increasing government funding for vaccine development

3.3.1.2.    Increasing vaccines R&D in developed nations

3.3.1.3.    Increasing disease prevalence in underdeveloped countries

3.3.1.4.    Growing incidences of cancer & HIV in Asia Pacific

3.3.2. Industry pitfalls & challenges

3.3.2.1.    High cost of vaccine storage and transportation

3.3.2.2.    Stringent regulations for the approval of vaccines in developed nations

3.4. Growth potential analysis

3.4.1. By age group

3.4.2. By technology

3.4.3. By disease

3.5. Regulatory landscape

3.5.1. U.S

3.5.2. Europe

3.5.3. Asia Pacific

3.6. Reimbursement scenario

3.6.1. U.S

3.6.2. Europe

3.7. Technology landscape

3.8. Pricing analysis

3.9. Pipeline product analysis

3.9.1. Malaria

3.9.2. HIV

3.9.3. Zika

3.9.4. Ebola

3.10. Porter’s analysis

3.11.  Company market share analysis, 2016

3.11.1.  Strategy dashboard

3.12. PESTEL analysis

Chapter 4. Vaccines Market, By Age group

4.1. Global vaccines market share by age group, 2016 & 2024

4.2. Pediatric

4.2.1. Market estimates and forecast, by region, 2013 - 2024

4.3. Adult

4.3.1. Market estimates and forecast, by region, 2013 - 2024

Chapter 5. Vaccines Market, By Technology

5.1. Vaccines market share by technology, 2016 & 2024

5.2. Attenuated

5.2.1. Market estimates and forecast, by region, 2013 - 2024

5.3. Toxoid

5.3.1. Market estimates and forecast, by region, 2013 – 2024

5.4. Conjugate

5.4.1. Market estimates and forecast, by region, 2013 – 2024

5.5. Inactivated & subunit

5.5.1. Market estimates and forecast, by region, 2013 – 2024

5.6. Recombinant

5.6.1. Market estimates and forecast, by region, 2013 – 2024

5.7. Others

5.7.1. Market estimates and forecast, by region, 2013 – 2024

Chapter 6. Vaccines Market, By Disease

6.1. Vaccines market share by disease, 2016 & 2024

6.2. Cancer

6.2.1. Market estimates and forecast, by region, 2013 – 2024

6.3. Hepatitis

6.3.1. Market estimates and forecast, by region, 2013 – 2024

6.4. Pneumococcal disease

6.4.1. Market estimates and forecast, by region, 2013 – 2024

6.5. DTP

6.5.1. Market estimates and forecast, by region, 2013 – 2024

6.6. Dengue

6.6.1. Market estimates and forecast, by region, 2013 – 2024

6.7. Influenza

6.7.1. Market estimates and forecast, by region, 2013 – 2024

6.8. Human papilloma virus

6.8.1. Market estimates and forecast, by region, 2013 – 2024

6.9. Meningococcal disease

6.9.1. Market estimates and forecast, by region, 2013 – 2024

6.10.    Polio

6.10.1.  Market estimates and forecast, by region, 2013 – 2024

6.11.    Rotavirus

6.11.1.  Market estimates and forecast, by region, 2013 – 2024

6.12.    Others

6.12.1.  Market estimates and forecast, by region, 2013 – 2024

Chapter 7. Vaccines Market, By Region

7.1. Vaccines market share by region, 2016 & 2024

7.2. North America

7.2.1. Market estimates and forecast, by country, 2013 – 2024

7.2.2. Market estimates and forecast, by age group, 2013 – 2024

7.2.3. Market estimates and forecast, by technology, 2013 – 2024

7.2.4. Market estimates and forecast, by disease, 2013 – 2024

7.2.5. U.S.

7.2.5.1.    Market estimates and forecast, by age group, 2013 – 2024

7.2.5.2.    Market estimates and forecast, by technology, 2013 – 2024

7.2.5.3.    Market estimates and forecast, by disease, 2013 – 2024

7.2.6. Canada

7.2.6.1.    Market estimates and forecast, by age group, 2013 – 2024

7.2.6.2.    Market estimates and forecast, by technology, 2013 – 2024

7.2.6.3.    Market estimates and forecast, by disease, 2013 – 2024

7.3. Europe

7.3.1. Market estimates and forecast, by country, 2013 – 2024

7.3.2. Market estimates and forecast, by age group, 2013 – 2024

7.3.3.    Market estimates and forecast, by technology, 2013 – 2024

7.3.4. Market estimates and forecast, by disease, 2013 – 2024

7.3.5. Germany

7.3.5.1.    Market estimates and forecast, by age group, 2013 – 2024

7.3.5.2.    Market estimates and forecast, by technology, 2013 – 2024

7.3.5.3.    Market estimates and forecast, by disease, 2013 – 2024

7.3.6. UK

7.3.6.1.    Market estimates and forecast, by age group, 2013 – 2024

7.3.6.2.    Market estimates and forecast, by technology, 2013 – 2024

7.3.6.3.    Market estimates and forecast, by disease, 2013 – 2024

7.3.7. Italy

7.3.7.1.    Market estimates and forecast, by age group, 2013 – 2024

7.3.7.2.    Market estimates and forecast, by technology, 2013 – 2024

7.3.7.3.    Market estimates and forecast, by disease, 2013 – 2024

7.3.8. France

7.3.8.1.    Market estimates and forecast, by age group, 2013 – 2024

7.3.8.2.    Market estimates and forecast, by technology, 2013 – 2024

7.3.8.3.    Market estimates and forecast, by disease, 2013 – 2024

7.3.9. Spain

7.3.9.1.    Market estimates and forecast, by age group, 2013 – 2024

7.3.9.2.    Market estimates and forecast, by technology, 2013 – 2024

7.3.9.3.    Market estimates and forecast, by disease, 2013 – 2024

7.3.10.  Russia

7.3.10.1.  Market estimates and forecast, by age group, 2013 – 2024

7.3.10.2.  Market estimates and forecast, by technology, 2013 – 2024

7.3.10.3.  Market estimates and forecast, by disease, 2013 – 2024

7.4. Asia Pacific

7.4.1. Market estimates and forecast, by country, 2013 – 2024

7.4.2. Market estimates and forecast, by age group, 2013 – 2024

7.4.3.    Market estimates and forecast, by technology, 2013 – 2024

7.4.4. Market estimates and forecast, by disease, 2013 – 2024

7.4.5. China

7.4.5.1.    Market estimates and forecast, by age group, 2013 – 2024

7.4.5.2.    Market estimates and forecast, by technology, 2013 – 2024

7.4.5.3.    Market estimates and forecast, by disease, 2013 – 2024

7.4.6. India

7.4.6.1.    Market estimates and forecast, by age group, 2013 – 2024

7.4.6.2.    Market estimates and forecast, by technology, 2013 – 2024

7.4.6.3.    Market estimates and forecast, by disease, 2013 – 2024

7.4.7. Japan

7.4.7.1.    Market estimates and forecast, by age group, 2013 – 2024

7.4.7.2.    Market estimates and forecast, by technology, 2013 – 2024

7.4.7.3.    Market estimates and forecast, by disease, 2013 – 2024

7.4.8. Indonesia

7.4.8.1.    Market estimates and forecast, by age group, 2013 – 2024

7.4.8.2.    Market estimates and forecast, by technology, 2013 – 2024

7.4.8.3.    Market estimates and forecast, by disease, 2013 – 2024

7.4.9. Australia

7.4.9.1.    Market estimates and forecast, by age group, 2013 – 2024

7.4.9.2.    Market estimates and forecast, by technology, 2013 – 2024

7.4.9.3.    Market estimates and forecast, by disease, 2013 – 2024

7.5. Latin America

7.5.1. Market estimates and forecast, by country, 2013 – 2024

7.5.2. Market estimates and forecast, by age group, 2013 – 2024

7.5.3.    Market estimates and forecast, by technology, 2013 – 2024

7.5.4. Market estimates and forecast, by disease, 2013 – 2024

7.5.5. Brazil

7.5.5.1.    Market estimates and forecast, by age group, 2013 – 2024

7.5.5.2.    Market estimates and forecast, by technology, 2013 – 2024

7.5.5.3.    Market estimates and forecast, by disease, 2013 – 2024

7.5.6. Mexico

7.5.6.1.    Market estimates and forecast, by age group, 2013 – 2024

7.5.6.2.    Market estimates and forecast, by technology, 2013 – 2024

7.5.6.3.    Market estimates and forecast, by disease, 2013 – 2024

7.5.7. Argentina

7.5.7.1.    Market estimates and forecast, by age group, 2013 – 2024

7.5.7.2.    Market estimates and forecast, by technology, 2013 – 2024

7.5.7.3.    Market estimates and forecast, by disease, 2013 – 2024

7.6. Middle East & Africa

7.6.1. Market estimates and forecast, by country, 2013 – 2024

7.6.2. Market estimates and forecast, by age group, 2013 – 2024

7.6.3.    Market estimates and forecast, by technology, 2013 – 2024

7.6.4. Market estimates and forecast, by disease, 2013 – 2024

7.6.5. South Africa

7.6.5.1.    Market estimates and forecast, by age group, 2013 – 2024

7.6.5.2.    Market estimates and forecast, by technology, 2013 – 2024

7.6.5.3.    Market estimates and forecast, by disease, 2013 – 2024

7.6.6. Saudi Arabia

7.6.6.1.    Market estimates and forecast, by age group, 2013 – 2024

7.6.6.2.    Market estimates and forecast, by technology, 2013 – 2024

7.6.6.3.    Market estimates and forecast, by disease, 2013 – 2024

7.6.7. UAE

7.6.7.1.    Market estimates and forecast, by age group, 2013 – 2024

7.6.7.2.    Market estimates and forecast, by technology, 2013 – 2024

7.6.7.3.    Market estimates and forecast, by disease, 2013 – 2024

7.6.8. Qatar

7.6.8.1.    Market estimates and forecast, by age group, 2013 – 2024

7.6.8.2.    Market estimates and forecast, by technology, 2013 – 2024

7.6.8.3.    Market estimates and forecast, by disease, 2013 – 2024

7.6.9. Egypt

7.6.9.1.    Market estimates and forecast, by age group, 2013 – 2024

7.6.9.2.    Market estimates and forecast, by technology, 2013 – 2024

7.6.9.3.    Market estimates and forecast, by disease, 2013 – 2024

Chapter 8. Company Profiles

8.1. AstraZeneca

8.1.1. Business Overview

8.1.2. Financial Data

8.1.3. Product Landscape

8.1.4. Strategic Outlook

8.1.5. SWOT Analysis

8.2. Abbott

8.2.1. Business Overview

8.2.2. Financial Data

8.2.3. Product Landscape

8.2.4. Strategic Outlook

8.2.5. SWOT Analysis

8.3. Bristol-Myers Squibb

8.3.1. Business Overview

8.3.2. Financial Data

8.3.3. Product Landscape

8.3.4. Strategic Outlook

8.3.5. SWOT Analysis

8.4. Merck & Co.

8.4.1. Business Overview

8.4.2. Financial Data

8.4.3. Product Landscape

8.4.4. Strategic Outlook

8.4.5. SWOT Analysis

8.5. Johnson & Johnson

8.5.1. Business Overview

8.5.2. Financial Data

8.5.3. Product Landscape

8.5.4. Strategic Outlook

8.5.5. SWOT Analysis

8.6. Sanofi Pasteur

8.6.1. Business Overview

8.6.2. Financial Data

8.6.3. Product Landscape

8.6.4. Strategic Outlook

8.6.5. SWOT Analysis

8.7. Pfizer

8.7.1. Business Overview

8.7.2. Financial Data

8.7.3. Product Landscape

8.7.4. Strategic Outlook

8.7.5. SWOT Analysis

8.8. GlaxoSmithKline

8.8.1. Business Overview

8.8.2. Financial Data

8.8.3. Product Landscape

8.8.4. Strategic Outlook

8.8.5. SWOT Analysis

8.9. Emergent BioSolutions

8.9.1. Business Overview

8.9.2. Financial Data

8.9.3. Product Landscape

8.9.4. Strategic Outlook

8.9.5. SWOT Analysis

8.10. Astellas Pharma

8.10.1.  Business Overview

8.10.2.  Financial Data

8.10.3.  Product Landscape

8.10.4.  Strategic Outlook

8.10.5.  SWOT Analysis

8.11. CSL

8.11.1.  Business Overview

8.11.2.  Financial Data

8.11.3.  Product Landscape

8.11.4.  Strategic Outlook

8.11.5.  SWOT Analysis

8.12.  Novavax

8.12.1.  Business Overview

8.12.2.  Financial Data

8.12.3.  Product Landscape

8.12.4.  Strategic Outlook

8.12.5.  SWOT Analysis

 

 

Data Tables

TABLE 1    Vaccines industry 3600 synopsis, 2013 – 2024    

TABLE 2    Global vaccines market estimates and forecast, 2013 – 2024     

TABLE 3    Global vaccines market estimates and forecast, by age group, 2013 – 2024     

TABLE 4    Global vaccines market estimates and forecast, by technology, 2013 – 2024     

TABLE 5    Global vaccines market estimates and forecast, by disease, 2013 – 2024     

TABLE 6    Global vaccines market estimates and forecast, by region, 2013 – 2024     

TABLE 7    Industry impact forces    

TABLE 8    Pediatric vaccines market estimates and forecast, by region, 2013 – 2024     

TABLE 9    Adult vaccines market estimates and forecast, by region, 2013 – 2024     

TABLE 10    Attenuated market estimates and forecast, by region, 2013 – 2024     

TABLE 11    Toxoid market estimates and forecast, by region, 2013 – 2024     

TABLE 12    Conjugate market estimates and forecast, by region, 2013 – 2024     

TABLE 13    Inactivated & subunit market estimates and forecast, by region, 2013 – 2024     

TABLE 14    Recombinant market estimates and forecast, by region, 2013 – 2024 

TABLE 15    Cancer vaccines market estimates and forecast, by region, 2013 – 2024     

TABLE 16    Hepatitis vaccines market estimates and forecast, by region, 2013 – 2024     

TABLE 17    Pneumococcal disease vaccines market estimates and forecast, by region, 2013 – 2024 

TABLE 18    DTP vaccines market estimates and forecast, by region, 2013 – 2024     

TABLE 19    Dengue vaccines market estimates and forecast, by region, 2013 – 2024     

TABLE 20    Influenza vaccines market estimates and forecast, by region, 2013 – 2024     

TABLE 21    Human papilloma virus vaccines market estimates and forecast, by region, 2013 – 2024 

TABLE 22    Meningococcal disease vaccines market estimates and forecast, by region, 2013 – 2024 

TABLE 23    Polio vaccines market estimates and forecast, by region, 2013 – 2024     

TABLE 24    Rotavirus vaccines market estimates and forecast, by region, 2013 – 2024     

TABLE 25    Rotavirus vaccines market estimates and forecast, by region, 2013 – 2024     

TABLE 26    North America vaccines market estimates and forecast, by country, 2013 - 2024    

TABLE 27    North America vaccines market estimates and forecast, by age group, 2013 - 2024     

TABLE 28    North America vaccines market estimates and forecast, by technology, 2013 - 2024     

TABLE 29    North America vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 30    U.S. vaccines market estimates and forecast, by age group, 2013 - 2024     

TABLE 31    U.S. vaccines market estimates and forecast, by technology, 2013 - 2024 

TABLE 32    U.S. vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 33    Canada vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 34    Canada vaccines market estimates and forecast, by technology, 2013 - 2024 

TABLE 35    Canada vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 36    Europe vaccines market estimates and forecast, by country 2013 - 2024     

TABLE 37    Europe vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 38    Europe vaccines market estimates and forecast, by technology, 2013 - 2024 

TABLE 39    Europe vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 40    Germany vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 41    Germany vaccines market estimates and forecast, by technology, 2013 - 2024     

TABLE 42    Germany vaccines market estimates and forecast, by disease, 2013 - 2024 

TABLE 43    UK vaccines market estimates and forecast, by age group, 2013 - 2024     

TABLE 44    UK vaccines market estimates and forecast, by technology, 2013 - 2024     

TABLE 45    UK vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 46    France vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 47    France vaccines market estimates and forecast, by technology, 2013 - 2024 

TABLE 48    France vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 49    Italy vaccines market estimates and forecast, by age group, 2013 - 2024     

TABLE 50    Italy vaccines market estimates and forecast, by technology, 2013 - 2024 

TABLE 51    Italy vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 52    Spain vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 53    Spain vaccines market estimates and forecast, by technology, 2013 - 2024 

TABLE 54    Spain vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 55    Russia vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 56    Russia vaccines market estimates and forecast, by technology, 2013 - 2024 

TABLE 57    Russia vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 58    Asia Pacific vaccines market estimates and forecast, by country, 2013 - 2024 

TABLE 59    Asia Pacific vaccines market estimates and forecast, by age group, 2013 - 2024     

TABLE 60    Asia Pacific vaccines market estimates and forecast, by technology, 2013 - 2024     

TABLE 61    Asia Pacific vaccines market estimates and forecast, by disease, 2013 - 2024 

TABLE 62    China vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 63    China vaccines market estimates and forecast, by technology, 2013 - 2024 

TABLE 64    China vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 65    India vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 66    India vaccines market estimates and forecast, by technology, 2013 - 2024 

TABLE 67    India vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 68    Japan vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 69    Japan vaccines market estimates and forecast, by technology, 2013 - 2024 

TABLE 70    Japan vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 71    Indonesia vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 72    Indonesia vaccines market estimates and forecast, by technology, 2013 - 2024     

TABLE 73    Indonesia vaccines market estimates and forecast, by disease, 2013 - 2024 

TABLE 74    Australia vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 75    Australia vaccines market estimates and forecast, by technology, 2013 - 2024     

TABLE 76    Australia vaccines market estimates and forecast, by disease, 2013 - 2024 

TABLE 77    Latin America vaccines market estimates and forecast, by country, 2013 – 2024     

TABLE 78    Latin America vaccines market estimates and forecast, by age group, 2013 - 2024     

TABLE 79    Latin America vaccines market estimates and forecast, by technology, 2013 - 2024     

TABLE 80    Latin America vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 81    Brazil vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 82    Brazil vaccines market estimates and forecast, by technology, 2013 - 2024 

TABLE 83    Brazil vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 84    Mexico vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 85    Mexico vaccines market estimates and forecast, by technology, 2013 - 2024 

TABLE 86    Mexico vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 87    Argentina vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 88    Argentina vaccines market estimates and forecast, by technology, 2013 - 2024     

TABLE 89    Argentina vaccines market estimates and forecast, by disease, 2013 - 2024 

TABLE 90    MEA vaccines market estimates and forecast, by country 2013 – 2024     

TABLE 91    MEA vaccines market estimates and forecast, by age group, 2013 - 2024     

TABLE 92    MEA vaccines market estimates and forecast, by technology, 2013 - 2024 

TABLE 93    MEA vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 94    South Africa vaccines market estimates and forecast, by age group, 2013 - 2024     

TABLE 95    South Africa vaccines market estimates and forecast, by technology, 2013 - 2024     

TABLE 96    South Africa vaccines market estimates and forecast, by disease, 2013 - 2024 

TABLE 97    Saudi Arabia vaccines market estimates and forecast, by age group, 2013 - 2024     

TABLE 98    Saudi Arabia vaccines market estimates and forecast, by technology, 2013 - 2024     

TABLE 99    Saudi Arabia vaccines market estimates and forecast, by disease, 2013 - 2024 

TABLE 100    UAE vaccines market estimates and forecast, by age group, 2013 - 2024     

TABLE 101    UAE vaccines market estimates and forecast, by technology, 2013 - 2024     

TABLE 102    UAE vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 103    Qatar vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 104    Qatar vaccines market estimates and forecast, by technology, 2013 - 2024 

TABLE 105    Qatar vaccines market estimates and forecast, by disease, 2013 - 2024     

TABLE 106    Egypt vaccines market estimates and forecast, by age group, 2013 - 2024 

TABLE 107    Egypt vaccines market estimates and forecast, by technology, 2013 - 2024 

TABLE 108    Egypt vaccines market estimates and forecast, by disease, 2013 - 2024 

 

Charts & Figures

FIG. 1    Industry segmentation

FIG. 2    Global vaccines market, 2013- 2024 (USD Billion)

FIG. 3    Growth potential analysis

FIG. 4    Porter’s analysis

FIG. 5    PESTEL analysis

FIG. 6    Vaccines market share by age group, 2016 & 2024

FIG. 7   Vaccines market share by technology, 2016 & 2024

FIG. 8   Vaccines market share by disease, 2016 & 2024

FIG. 9    Vaccines market share, by region, 2016 & 2024

 

Why Global Market Insights?

 Comprehensive Research
  • All-inclusive coverage
  • In-depth and granular data (ex: information for 8 to 15 countries, with clients open to add to this list, in each report)
  • Penetrative insights & latest trends
  • Offers holistic understanding of the market
 Data Accuracy & Reliability
  • Unique methodology
  • Iterative in nature to eliminate errors
  • Detailed methodology, scope, assumptions and data sources available for reference
 Post-Sales Support
  • Committed to making a positive difference for our clients
  • Given the nature of this industry, we are committed to ensure that our clients get maximum return on their investment in our services
  • Every purchase comes with an option to obtain additional information:
    • up to 10% of the original cost
    • 45-minute analyst tele-call to obtain further clarity on the market.
 Security & Confidentiality
  • Global Market Insights, Inc. strictly adheres to PCI-DSS security norms.
  • Only PCI-DSS compliant payment methods used for highest level of client data security

Tailor this report

Customize this report to suit your needs, speak to our research team to avail these benefits


Connect with our sales team